Kære Kollega,
Vedlagt invitation fra Dansk GlaukomSelskab til vores årsmøde.
Årsmødet afholdes  på "store bededag",
fredag d. 26. april 2024
på Marienlyst strandhotel i Helsingør.
Download program

Vi har den meget store fornøjelse at præsentere toppen af poppen:
Professor emeritus, Donald Hood vil sammen med K. Mercieca og M. Tsamis fortælle os om 
OCT og glaukomatøse forandringer herunder synsfelter for basis for kliniske beslutninger.

Vil Du gerne opfriskes på OCT og synsfelter samt høre Donald HOOD, får Du her en unik mulighed.

Deltagelse er gratis for medlemmer af Dansk GlaukomSelskab og foregår efter "først til mølle"-princippet.

Med ønsket om en glædelig jul og et fredeligt og lykkebringende nytår
Dansk GlaukomSelskab

Original-artiklen fra The Lancet:

Summary
Primary open angle glaucoma and ocular hypertension are habitually treated with eye drops that lower intraocular pressure. Selective laser trabeculoplasty is a safe alternative but is rarely used as first-line treatment. We compared the two.

Methods
In this observer-masked, randomised controlled trial treatment-naive patients with open angle glaucoma or ocular hypertension and no ocular comorbidities were recruited between 2012 and 2014 at six UK hospitals. They were randomly allocated (web-based randomisation) to initial selective laser trabeculoplasty or to eye drops. An objective target intraocular pressure was set according to glaucoma severity. The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness, and safety. Analysis was by intention to treat. This study is registered at controlled-trials.com (ISRCTN32038223).

Findings
Of 718 patients enrolled, 356 were randomised to the selective laser trabeculoplasty and 362 to the eye drops group. 652 (91%) returned the primary outcome questionnaire at 36 months. Average EQ-5D score was 0·89 (SD 0·18) in the selective laser trabeculoplasty group versus 0·90 (SD 0·16) in the eye drops group, with no significant difference (difference 0·01, 95% CI −0·01 to 0·03; p=0·23). At 36 months, 74·2% (95% CI 69·3–78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target. Eyes of patients in the selective laser trabeculoplasty group were within target intracoluar pressure at more visits (93·0%) than in the eye drops group (91·3%), with glaucoma surgery to lower intraocular pressure required in none versus 11 patients. Over 36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted life-year gained.

Interpretation
Selective laser trabeculoplasty should be offered as a first-line treatment for open angle glaucoma and ocular hypertension, supporting a change in clinical practice.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32213-X/fulltext